Transition Bio, Inc., a Cambridge, MA- and Cambridge, UK-based provider of a microfluidics-driven drug discovery platform using biophysical sciences and artificial intelligence tools to map and modulate biomolecular condensates, raised $50 Million in Series A financing.
The round was led by Northpond Ventures and joined by Taiho Ventures, Bristol Myers Squibb, and Magnetic Ventures. Lifeforce Capital, the lead investor from the seed financing, also participated and was joined by other existing seed investors.
The funding allows rapid expansion of the technology by scaling up the platform and translating the science across a variety of targets and disease areas.
Company: Transition Bio, LLC.
Round: Series A
Funding Month: June 2022
Lead Investors: Northpond Ventures
Additional Investors: Taiho Ventures, Bristol Myers Squibb, Magnetic Ventures, and Lifeforce Capital
Company Website: https://transitionbio.com/
Software Category: Drug Discovery platform
About the Company: Led by Greg Miller, chief executive officer, Transition Bio is a provider of a microfluidics-driven drug discovery platform that utilizes microfluidics to drive the high-throughput generation of proprietary data to enable machine learning-guided condensate target identification and drug discovery. Transition Bio is developing one-of-a-kind technologies for biomolecular condensate analysis. Through the Condensomics platform,